Kowalski A, Lykon J, Diamond B, Coffey DG, Kaddoura M, Maura F, Hoffman JE, Kazandjian D, Landgren O. Emerging Strategies for the Prevention of Immune Toxicities Associated with T cell-Engaging Cancer Therapies.
Blood Cancer Discov 2024;
5:90-94. [PMID:
38175152 PMCID:
PMC10905506 DOI:
10.1158/2643-3230.bcd-23-0228]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2023] [Revised: 12/15/2023] [Accepted: 12/15/2023] [Indexed: 01/05/2024] Open
Abstract
SUMMARY
Immune-related toxicities including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are common side effects of bispecific antibody and chimeric antigen receptor (CAR) T-cell therapies of hematologic malignancies. As anti-inflammatory therapy (the standard of care) is variably effective in mitigating these toxicities after onset, here we discuss emerging evidence for shifting the strategy from mitigation to prevention.
Collapse